Zepbound (tirzepatide) helps improve obstructive sleep apnea (OSA) in adults with obesity by causing substantial weight loss, which reduces upper‑airway blockage during sleep and lowers the number of breathing disruptions measured by the apnea‑hypopnea index (AHI). This may help improve symptoms like reduced sleep quality and daytime sleepiness.

What Does Zepbound Do for Sleep Apnea?

Zepbound is the first U.S. prescription medicine approved to treat moderate‑to‑severe obstructive sleep apnea (OSA) in adults with obesity. By helping people lose a significant amount of body weight, it can lower the number of times per hour that breathing stops (apnea) or becomes shallow (hypopnea) during sleep.

In studies of adults with OSA and obesity, people taking Zepbound had an average reduction of about 25 to 29 breathing disruptions per hour, compared to about 5 to 6 fewer events in those taking placebo (an injection with no medicine). Patients with OSA also lost an average of 18% to 20% of their body weight (about 45 to 50 pounds), which is thought to be the main reason their OSA improved.

Zepbound was shown to help OSA whether or not patients were also using positive airway pressure (PAP) therapy during the study. In both situations, roughly one‑half of participants no longer had symptoms associated with OSA or had only mild, non‑symptomatic OSA after one year.

How Does Zepbound Work in the Body?

Zepbound, manufactured by Eli Lilly, is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by activating hormone receptors to reduce appetite and food intake, leading to weight loss that may improve OSA symptoms.

For obstructive sleep apnea, this weight loss is important because extra fat in the neck, tongue, and upper airway can narrow the breathing passage. As body weight and fat around the upper airway decrease, the throat is less likely to collapse during sleep, which helps lower AHI, improve nighttime breathing, and reduce symptoms such as snoring and daytime sleepiness.

When was Zepbound Approved for Sleep Apnea?

Zepbound was approved for OSA in December 2024 and is the first U.S. prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. It was also previously approved in November 2023 to help reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight who also have weight-related medical problems.

Tirzepatide, the active ingredient in Zepbound, was first approved under the brand name Mounjaro (also from Eli Lilly) in May 2022 to improve glycemic (blood sugar) control in adults with type 2 diabetes. It is not known if Zepbound is safe and effective for use in children.

Studies of Zepbound for Sleep Apnea

Approval for Zepbound use in obstructive sleep apnea (OSA) was based on the SURMOUNT-OSA Phase 3 global studies with 469 participants with OSA unable or unwilling to use positive airway pressure (PAP). In two studies, Zepbound was evaluated for the treatment of OSA in adults with obesity, with and without the use of PAP therapy over one year. Patients did not have type 2 diabetes.

The primary objective of this study was to show that Zepbound was superior to a placebo treatment (an injection with no medicine) in the change in apnea-hypopnea index (AHI) over one year.

The apnea-hypopnea index (AHI) measures the severity of OSA and looks at the number of times per hour during sleep that breathing stops (apnea) or becomes significantly reduced (hypopnea).

Results

Zepbound was found to be about 5 times more effective than placebo, and results were statistically and clinically significant.

• Studies in adults with moderate-to-severe obstructive sleep apnea (OSA) who were not using positive airway pressure (PAP) therapy showed that Zepbound led to 25 fewer breathing disruptions per hour compared to 5 disruptions with placebo, as measured by AHI.
• In patients who were using PAP, Zepbound led to 29 fewer breathing disruptions per hour compared to 6 disruptions with placebo, as measured by AHI.

The improvement in AHI in participants with OSA is likely related to body weight reduction with Zepbound.

• In addition to improved OSA symptoms, adults on Zepbound lost an average of 18% of their body weight (45 lbs / 20.5 kg), while adults using Zepbound and PAP therapy lost an average of 20% of their body weight (50 lbs or 22.7 kg).
• This was compared to the placebo group which lost 4 lbs (1.8 kg) and 6 lbs (2.7 kg) (about 2% of body weight, on average), respectively.

After one year in two different studies, 42% or 50% of adults on Zepbound had no sleep apnea (remission) or mild, non-symptomatic OSA, compared to 16% or 14% using a placebo.

Also, patients treated with Zepbound achieved a greater reduction in systolic blood pressure and high-sensitivity C-reactive protein levels compared to placebo. Patients also reported improved sleep.

Side effects with Zepbound

In the obstructive sleep apnea studies, the most frequently reported adverse events were related to the stomach, and found to be primarily mild to moderate in severity.

The most common adverse reactions with Zepbound include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Stomach area pain
• Indigestion
• Injection site reactions
• Fatigue
• Allergic reactions (typically fever and rash)
• Belching
• Hair loss
• Heartburn

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products (like Mounjaro) or any GLP-1 receptor agonist medicines.

Zepbound causes thyroid C-cell tumors in rats. It is unknown whether Zepbound causes such tumors, including medullary thyroid cancer, in humans. Zepbound should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.

These are not all the possible side effects of Zepbound. If you are concerned about any side effects with use of this medicine, speak to your healthcare provider.

Related questions

• Zepbound vs Mounjaro: Comparison Guide for Weight Loss and Diabetes Treatment
• Which GLP-1 drug is best for weight loss?
• Tirzepatide vs semaglutide: How do they compare?

What is Obstructive Sleep Apnea?

Obstructive sleep apnea (OSA) is a serious breathing disorder that is characterized by complete or partial collapses of the upper airway during sleep. This may lead to pauses in breathing, shallow breathing, waking up from sleep and a potential decrease in blood oxygen. Snoring, fatigue and excessive daytime sleepiness are key symptoms of OSA.

While OSA can affect anyone, it is more common in people who have obesity or overweight. This is because excess soft tissue around the neck and tongue can narrow the airway and make it more likely to collapse when muscles relax during sleep.

Positive airway pressure (PAP) is the standard of care for moderate to severe OSA. PAP is a general term for the machines used during sleep that push air under pressure into the lungs to help prevent apnea. There are several different types of PAP machines, including continuous PAP (CPAP).

How is Zepbound Given for Sleep Apnea?

Zepbound is given as a subcutaneous (under the skin) injection in your stomach area, thigh or upper arm. It is used once per week, at any time of the day. It should be taken in addition to a reduced-calorie diet and increased physical activity. Your healthcare provider will teach you how to inject the medicine, so it can be used at home.

To help reduce stomach‑related side effects such as nausea, vomiting, diarrhea, or constipation, you will typically start at a lower dose and increase gradually. Your doctor will adjust your dose to find the best long‑term (maintenance) dose you can tolerate. Doses can be given with or without food.

• The recommended starting dosage is 2.5 mg injected subcutaneously (under the skin) once weekly for 4 weeks
• The recommended maintenance dose for obstructive sleep apnea (OSA) is 10 mg or 15 mg injected subcutaneously once weekly.

Your doctor will prescribe your dose and schedule for injections. Follow their instructions carefully, and do not change your dose or stop treatment without talking with your healthcare provider.

Does Zepbound Cure Sleep Apnea or Replace CPAP?

Zepbound can greatly improve OSA by lowering AHI and helping some adults reach mild OSA or remission, especially when substantial weight loss is achieved. However, it is not considered a guaranteed cure for sleep apnea, and medication alone may not fully normalize breathing or oxygen levels in all patients, particularly if their OSA is driven by anatomical factors beyond weight.

Positive airway pressure (PAP), including continuous PAP (CPAP), remains the standard of care for moderate‑to‑severe OSA, and many people will use Zepbound together with PAP rather than instead of it. Decisions about lowering or stopping PAP should always be guided by your healthcare provider and usually require a follow‑up sleep study to confirm sustained improvement in AHI and oxygen levels.

How Long Does it Take Zepbound to Work for Sleep Apnea?

In the SURMOUNT‑OSA studies, benefits on AHI and weight built gradually over the 52‑week treatment period, with the largest improvements seen after patients reached their maintenance dose and sustained weight loss. Some people may notice improvements in daytime sleepiness or snoring earlier, but it may take several months to see the full effect on OSA severity on a repeat sleep study.

Your healthcare provider may check in regularly about side effects, weight changes, and symptoms such as daytime tiredness or morning headaches and may recommend a follow‑up sleep study after you have been on a stable dose for a period of time.

Does Zepbound Help with Snoring?

Because Zepbound can reduce the severity of OSA and the number of airway collapses during sleep, many patients may notice less loud snoring as their weight and AHI improve. However, snoring alone is not a reliable way to measure OSA severity, and it is possible to snore even after sleep apnea has improved—or to have OSA with minimal snoring. If you are using Zepbound for OSA, your doctor may recommend formal sleep testing rather than relying on snoring to track your progress.

This is not all the information you need to know about Zepbound (tirzepatide) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

References

• Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21. Erratum in: N Engl J Med. 2024 Oct 17;391(15):1464. doi: 10.1056/NEJMx240005. PMID: 38912654; PMCID: PMC11598664
• Zepbound [prescribing information]. Updated January 2026. Indianapolis, IN. Eli Lilly and Co. Accessed 02/10/2026 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
• FDA Approves First Medication for Obstructive Sleep Apnea. US Food and Drug Administration (FDA). Dec. 20, 2024. Press Announcements. Accessed Dec. 23, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
• FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity. Dec. 20, 2024. Drugs.com. Accessed Dec. 23, 2024 at https://www.drugs.com/newdrugs/fda-approves-imaavy-nipocalimab-aahu-generalized-myasthenia-gravis-gmg-6509.html

Read next

See also:

Related medical questions

• How long does it take for Zepbound to work?
• What should I eat (or avoid) while taking Zepbound?
• Zepbound vs Wegovy: What's the diference between them?
• Can you get tirzepatide from a compounding pharmacy?
• How does Foundayo compare to Zepbound for weight loss?
• How much weight can I lose on Zepbound?
• Is Zepbound covered by insurance?
• What happens when you stop taking Zepbound?
• How long do Zepbound side effects typically last?
• How do you switch from Wegovy or Zepbound to Foundayo?
• Why can Zepbound cause headaches and what to do about it?
• Why am I not losing weight on Zepbound?
• Will medicare cover Zepbound?
• Can you take Zepbound, Mounjaro or Ozempic a day early?
• Medicare GLP-1 Bridge Program: Cost & Eligibility
• How do you dispose of Mounjaro, Zepbound and other GLP-1 injection pens?
• How do you inject / administer Zepbound?
• How to get prescribed a GLP-1 like Ozempic, Zepbound, Mounjaro or Wegovy?
• MariTide vs Wegovy or Zepbound: how do they compare?
• How do I know if I have sleep apnea? The warning signs
• What is the Zepbound Coupon or Savings Card?
• Is sleep apnea the hidden cause of your high blood pressure?
• Can Zepbound and Mounjaro be used for heart failure?
• How long does it take for Mounjaro (tirzepatide) to start working?
• Retatrutide vs tirzepatide: how do they compare?
• Does tirzepatide cause cancer?
• Is there a tirzepatide pill, and does it work?
• Can Mounjaro (tirzepatide) cause depression and anxiety?
• Can Mounjaro (tirzepatide) cause high blood pressure?
• Does Mounjaro (tirzepatide) cause muscle loss?

Drug information

• Zepbound (782 reviews)
• Tirzepatide (3,499 reviews)

Related support groups

• Zepbound (36 questions, 57 members)
• Tirzepatide (26 questions, 20 members)
• Weight Loss (Obesity/Overweight) (903 questions, 1,533 members)
• Obstructive Sleep Apnea/Hypopnea Syndrome (35 questions, 59 members)
• Sleep Apnea (21 questions, 105 members)

Medical Disclaimer